The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 6, 2013, Pages 505-510

  Maranghi, M ^a   Prudente, S ^b   D'Erasmo, L ^a   Morini, E ^b   Ciociola, E ^a   Coletta, P ^a   Verrienti, A ^a   Arciello, S ^a   Copetti, M ^b   Pellegrini, F ^b,c   Santini, S A ^b   Morano, S ^a   Filetti, S ^a   Trischitta, V ^a,b,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c IRCCS Casa Sollievo della Sofferenza ^*  (Italy)

^d Istituto Mendel   (Italy)

Author keywords

Gene treatment interaction; Insulin resistance; Insulin signalling; Lifestyle intervention; Overweight obesity; Prevention of type 2 diabetes mellitus

Indexed keywords

ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INORGANIC PYROPHOSPHATASE; PHOSPHODIESTERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BODY MASS; DIABETES MELLITUS; DIET; DIET RESTRICTION; EXERCISE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INTERVENTION STUDY; LIFESTYLE; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; WEIGHT REDUCTION;

ADIPOSITY; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS; DIET; EXERCISE; FASTING; FEMALE; GENOTYPE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INTERVENTION STUDIES; LIFE STYLE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT; PHOSPHORIC DIESTER HYDROLASES; POLYMORPHISM, GENETIC; PYROPHOSPHATASES; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84878933515     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.11.003     Document Type: Article

References (26)

1. WJHaK A.S. Epidemiology of diabetes mellitus. Joslin's diabetes mellitus 2005, 341-354. W.W.N.Y. Lippincott (Ed.).
2. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365(9467):1333-1346. 10.1016/S0140-6736(05)61032-X.
3. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by change in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
4. Goldfine I.D., Maddux B.A., Youngren J.F., Reaven G., Accili D., Trischitta V., et al. The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev 2008, 29(1):62-75.
5. Maddux B.A., Sbraccia P., Kumakura S., Sasson S., Youngren J., Fisher A., et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995, 373:448-451.
6. Frittitta L., Youngren J.F., Sbraccia P., D'Adamo M., Buongiorno A., Vigneri R., et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia 1997, 40:282-289.
7. Frittitta L., Spampinato D., Solini A., Nosadini R., Goldfine I.D., Vigneri R., et al. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased invivo and invitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes 1998, 47:1095-1100.
8. Stentz F.B., Kitabchi A.E. Transcriptome and proteome expressions involved in insulin resistance in muscle and activated T-lymphocytes of patients with type 2 diabetes. Genomics Proteomics Bioinform 2007, 5:216-235.
9. Pizzuti A., Frittitta L., Argiolas A., Baratta R., Goldfine I.D., Bozzali M., et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes 1999, 48:1881-1884.
10. Costanzo B.V., Trischitta V., Di Paola R., Spampinato D., Pizzuti A., Vigneri R., et al. The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes 2001, 50:831-836.
11. Bacci S., Di Paola R., Menzaghi C., Di Fulvio P., Di Silvestre S., Pellegrini F., et al. ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cells. Arterioscler Thromb Vasc Biol 2009, 29:1678-1683.
12. Di Paola R., Caporarello N., Marucci A., Dimatteo C., Iadicicco C., Del Guerra S., et al. ENPP1 affects insulin action and secretion: evidences from invitro studies. PLoS ONE 2011, 6(5). e19462.
13. Wang R., Zhou D., Xi B., Ge X., Zhu P., Wang B., et al. ENPP1/PC-1 gene K121Q polymorphism is associated with obesity in European adult populations: evidence from a meta-analysis involving 24,324 subjects. Biomed Environ Sci 2011, 24:200-206. 10.3967/0895-3988.2011.02.015.
14. Abate N., Chandalia M., Satija P., Adams-Huet B., Grundy S.M., Sandeep S., et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes 2005, 54:1207-1213.
15. Grarup N., Urhammer S.A., Ek J., Albrechtsen A., Glümer C., Borch-Johnsen K., et al. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia 2006, 49:2097-2104.
16. Stolerman E.S., Manning A.K., McAteer J.B., Dupuis J., Fox C.S., Cupples L.A., et al. Haplotype structure of the ENPP1 gene and nominal association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham Heart Study. Diabetes 2008, 57:1971-1977.
17. Baratta R., Rossetti P., Prudente S., Barbetti F., Sudano D., Nigro A., et al. Role of the ENPP1 K121Q polymorphism in glucose homeostasis. Diabetes 2008, 57:3360-3364.
18. Meyre D., Bouatia-Naji N., Tounian A., Samson C., Lecoeur C., Vatin V., et al. Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet 2005, 37:863-867. Epub 2005 Jul 17. 10.1038/ng1604.
19. Bochenski J., Placha G., Wanic K., Malecki M., Sieradzki J., Warram J.H., et al. New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals. Diabetes 2006, 55:2626-2630.
20. McAteer J.B., Prudente S., Bacci S., Lyon H.N., Hirschhorn J.N., Trischitta V., et al. The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 2008, 57:1125-1130. Epub 2007 Dec 10. 10.2337/db07-1336.
21. Cauchi S., Nead K.T., Choquet H., Horber F., Potoczna N., Balkau B., et al. The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. BMC Med Genet 2008, 9:45.
22. El Achhab Y., Meyre D., Bouatia-Naji N., Berraho M., Deweirder M., Vatin V., et al. M. Association of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population. Diabetes Metab 2009, 35:37-42. Epub 2008 Nov28. 10.1016/j.diabet.2008.06.005.
23. Prudente S., Morini E., Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol 2009, 5:682-693.
24. Moore A.F., Jablonski K.A., Mason C.C., McAteer J.B., Arakaki R.F., Goldstein B.J., et al. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab 2009, 94:449-455.
25. Müssig K., Heni M., Thamer C., Kantartzis K., Machicao F., Stefan N., et al. The ENPP1 K121Q polymorphism determines individual susceptibility to the insulin-sensitising effect of lifestyle intervention. Diabetologia 2010, 53:504-509.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.